Stock Financial Ratios, Dividends, Split History

HHC / Howard Hughes Corp. (The) financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price133.43
Volume163,500.00
Market Cap ($M)5,969.11
Book Value ($M)3,073.44
Book Value / Share73.42
Price / Book1.88
NCAV ($M)-3,540.51
NCAV / Share-81.67
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 43,351,812
Weighted Average Number Of Diluted Shares Outstanding 43,089
Common Stock Shares Outstanding 43,270,880
Weighted Average Number Of Shares Outstanding Basic 41,364
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.03
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Assets6,737.99
Liabilities3,658.62
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues1,100,120,000.00
Builder Price Participation Revenue22,835,000.00
Real Estate Partnership Revenue0.00
Condominium Unit Sales Revenue0.00
Hospitality Revenues76,020,000.00
Condominium Rights And Unit Sales Revenue464,251,000.00
Revenue From Owned Hotels0.00
Equity Method Investment Summarized Financial Information Revenue58,600,000.00
Other Land Revenues28,166,000.00
Resort And Conference Center Revenues0.00
Other Real Estate Revenue31,414,000.00
Operating Income218.50
Net Income166.62
Earnings Per Share Diluted3.91
Earnings Per Share Basic4.07
Cash Flow Statement (mra) ($M)
Cash From Operations319.03
Cash from Investing-322.68
Cash from Financing-322.68
Identifiers and Descriptors
CUSIP44267D107
Central Index Key (CIK)1498828
Related CUSIPS
44267D957 44267D907

Split History

Stock splits are used by Howard Hughes Corp. (The) to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

A Macy's goes from mall mainstay to homeless shelter

2018-06-14 cnbc
ALEXANDRIA, Va. — Karleen Smith used to work at the Macy's in Landmark Mall, putting price tags on summer dresses, housewares and the latest styles of shoes. (8-0)

Draining The Swamp: How The St. Joe Company Has Evolved Into The Ultimate Real Estate Moat

2018-05-18 seekingalpha
Began purchasing shares of St. Joe (JOE) in mid-2017 as it became clear the Company was finally in position to fully capitalize on the inherent value of its assets. (9-0)

Tracking Bill Ackman's Pershing Square Portfolio - Q1 2018 Update

2018-05-16 seekingalpha
The largest three 13F positions are Restaurant Brands International, Chipotle Mexican Grill, and Automatic Data Processing and together they account for around two-thirds of the portfolio. (163-0)

Howard Hughes 2017 Annual Review

2018-05-03 seekingalpha
(4-0)

Howard Hughes Corp's (HHC) CEO David Weinreb on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
The Howard Hughes Corporation (NYSE:HHC) Q1 2018 Earnings Conference Call May 2, 2018 11:00 AM ET (34-0)

CUSIP: 44267D107